首页 > 最新文献

Endocrine Practice最新文献

英文 中文
Exploring the Link Between Thyroid Disorders and Obesity: Mechanisms, Impacts, and Clinical Implications.
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-12 DOI: 10.1016/j.eprac.2025.02.005
Ashni Dharia, Dimpi Desai, Kaniksha Desai

Objective: Obesity and thyroid dysfunction are among the most significant challenges in endocrinology, frequently overlapping to create complexities in weight management. Even after achieving euthyroidism, weight variations persist, significantly affecting patients' quality of life. This review explores the mechanisms linking hypothyroidism and hyperthyroidism to weight fluctuations, emphasizing their impact on basal metabolic rate, appetite regulation, glucose and lipid metabolism, and thermogenesis.

Methods: We conducted a comprehensive review using PubMed and Google Scholar, applying the search criteria: (obesity OR overweight) AND (Hashimoto's thyroiditis OR hyperthyroidism OR hypothyroidism OR Thyroid Cancer). From this search, we reviewed 500 publications and finally included 71 publications, focusing on broad clinical questions regarding the role of thyroid hormones in weight regulation and metabolism, the impact of thyroid disorders and their treatments on obesity, and approaches for managing obesity in the context of thyroid dysfunction.

Results: In hypothyroidism, the impact of levothyroxine therapy on weight changes is discussed, along with the potential role of T3 supplementation. For hyperthyroid patients, the effects of antithyroid medications, radioactive iodine therapy, and thyroidectomy on weight regulation are explored. Pharmacological and nonpharmacological strategies for managing obesity in thyroid disorders are reviewed. Lifestyle interventions and pharmacotherapies are evaluated for their efficacy and potential effects on thyroid function. Lastly, the implications of bariatric surgery are explored, including its effects on thyroid function, medication absorption, and postsurgical management of thyroid disorders.

Conclusion: This review underscores the importance of an integrated, multidisciplinary approach to managing obesity in the context of thyroid dysfunction to optimize patient outcomes.

{"title":"Exploring the Link Between Thyroid Disorders and Obesity: Mechanisms, Impacts, and Clinical Implications.","authors":"Ashni Dharia, Dimpi Desai, Kaniksha Desai","doi":"10.1016/j.eprac.2025.02.005","DOIUrl":"10.1016/j.eprac.2025.02.005","url":null,"abstract":"<p><strong>Objective: </strong>Obesity and thyroid dysfunction are among the most significant challenges in endocrinology, frequently overlapping to create complexities in weight management. Even after achieving euthyroidism, weight variations persist, significantly affecting patients' quality of life. This review explores the mechanisms linking hypothyroidism and hyperthyroidism to weight fluctuations, emphasizing their impact on basal metabolic rate, appetite regulation, glucose and lipid metabolism, and thermogenesis.</p><p><strong>Methods: </strong>We conducted a comprehensive review using PubMed and Google Scholar, applying the search criteria: (obesity OR overweight) AND (Hashimoto's thyroiditis OR hyperthyroidism OR hypothyroidism OR Thyroid Cancer). From this search, we reviewed 500 publications and finally included 71 publications, focusing on broad clinical questions regarding the role of thyroid hormones in weight regulation and metabolism, the impact of thyroid disorders and their treatments on obesity, and approaches for managing obesity in the context of thyroid dysfunction.</p><p><strong>Results: </strong>In hypothyroidism, the impact of levothyroxine therapy on weight changes is discussed, along with the potential role of T3 supplementation. For hyperthyroid patients, the effects of antithyroid medications, radioactive iodine therapy, and thyroidectomy on weight regulation are explored. Pharmacological and nonpharmacological strategies for managing obesity in thyroid disorders are reviewed. Lifestyle interventions and pharmacotherapies are evaluated for their efficacy and potential effects on thyroid function. Lastly, the implications of bariatric surgery are explored, including its effects on thyroid function, medication absorption, and postsurgical management of thyroid disorders.</p><p><strong>Conclusion: </strong>This review underscores the importance of an integrated, multidisciplinary approach to managing obesity in the context of thyroid dysfunction to optimize patient outcomes.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Impact of Thyroid Eye Disease on Quality of Life: Insights From a Retrospective Cohort Study.
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-11 DOI: 10.1016/j.eprac.2025.02.003
Jan Schovanek, Martin Radvansky, Marta Karhanova, Marie Bolacka, Klara Pekarova, Roman Dohnal, Martin Radvansky, Milos Kudelka, Eva Kriegova, David Karasek

Objectives: Thyroid eye disease (TED) seriously affects patients' quality of life (QoL), even if the disease is stable and nonactive. Data on clinical factors negatively influencing the QoL of patients with TED and long-term outcomes are limited. This study aims to evaluate the lasting impact of TED on QoL, focusing on the effects of previous TED treatments and identifying factors influencing long-term outcomes.

Methods: A retrospective cohort study included 151 patients treated for active, moderate-to-severe and severe TED, with a mean follow-up of 8 years.

Results: Higher clinical activity scores at diagnosis correlated with lower QoL scores. Thyroidectomy before immunosuppressive treatment was associated with lower QoL and an increased likelihood of orbital decompression. Any disease progression necessitating second-line treatments also negatively affected QoL. A decrease in thyrotropin receptor antibodies during active treatment and early treatment initiation positively affected visual functioning. Time-dependent regression analysis demonstrated no significant trend in QoL changes over time.

Conclusion: Our data reveal that disease severity, the timing of interventions and disease progression contribute to less favorable long-term QoL outcomes, extending years beyond active treatment. Early and accurate diagnosis and appropriate treatment can minimize poor long-term QoL in patients with TED.

{"title":"Long-Term Impact of Thyroid Eye Disease on Quality of Life: Insights From a Retrospective Cohort Study.","authors":"Jan Schovanek, Martin Radvansky, Marta Karhanova, Marie Bolacka, Klara Pekarova, Roman Dohnal, Martin Radvansky, Milos Kudelka, Eva Kriegova, David Karasek","doi":"10.1016/j.eprac.2025.02.003","DOIUrl":"10.1016/j.eprac.2025.02.003","url":null,"abstract":"<p><strong>Objectives: </strong>Thyroid eye disease (TED) seriously affects patients' quality of life (QoL), even if the disease is stable and nonactive. Data on clinical factors negatively influencing the QoL of patients with TED and long-term outcomes are limited. This study aims to evaluate the lasting impact of TED on QoL, focusing on the effects of previous TED treatments and identifying factors influencing long-term outcomes.</p><p><strong>Methods: </strong>A retrospective cohort study included 151 patients treated for active, moderate-to-severe and severe TED, with a mean follow-up of 8 years.</p><p><strong>Results: </strong>Higher clinical activity scores at diagnosis correlated with lower QoL scores. Thyroidectomy before immunosuppressive treatment was associated with lower QoL and an increased likelihood of orbital decompression. Any disease progression necessitating second-line treatments also negatively affected QoL. A decrease in thyrotropin receptor antibodies during active treatment and early treatment initiation positively affected visual functioning. Time-dependent regression analysis demonstrated no significant trend in QoL changes over time.</p><p><strong>Conclusion: </strong>Our data reveal that disease severity, the timing of interventions and disease progression contribute to less favorable long-term QoL outcomes, extending years beyond active treatment. Early and accurate diagnosis and appropriate treatment can minimize poor long-term QoL in patients with TED.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Central Hypothyroidism: Advances in Etiology, Diagnostic Challenges, Therapeutic Targets, and Associated Risks.
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-11 DOI: 10.1016/j.eprac.2025.02.004
Pedro Iglesias

Objective: Central hypothyroidism is a rare disorder resulting from impaired thyroid hormone production due to deficiencies in TSH secretion from the pituitary or TRH secretion from the hypothalamus. This review aims to summarize recent advances in the etiology, diagnosis, and treatment of central hypothyroidism, with an emphasis on diagnostic and therapeutic challenges.

Methods: A comprehensive review of the literature was conducted, focusing on genetic and acquired causes, particularly those related to hypothalamic-pituitary tumors and the effects of surgical and radiotherapeutic interventions. Diagnostic approaches and treatment strategies, including levothyroxine therapy and monitoring, are analyzed.

Results: Early diagnosis requires simultaneous measurement of free T4 and TSH to prevent neurological sequelae, especially in congenital cases. Central hypothyroidism is associated with risks such as growth and developmental impairment, as well as metabolic and cardiovascular disturbances. Levothyroxine therapy is crucial for correcting hormonal deficits and improving patient outcomes; however, careful dosing is necessary to avoid potential complications, particularly in vulnerable populations.

Conclusions: Personalized treatment and continuous monitoring are essential to optimize clinical outcomes and enhance the quality of life in affected individuals. A thorough understanding of central hypothyroidism's etiology and management is necessary to improve early detection and therapeutic strategies.

{"title":"Central Hypothyroidism: Advances in Etiology, Diagnostic Challenges, Therapeutic Targets, and Associated Risks.","authors":"Pedro Iglesias","doi":"10.1016/j.eprac.2025.02.004","DOIUrl":"10.1016/j.eprac.2025.02.004","url":null,"abstract":"<p><strong>Objective: </strong>Central hypothyroidism is a rare disorder resulting from impaired thyroid hormone production due to deficiencies in TSH secretion from the pituitary or TRH secretion from the hypothalamus. This review aims to summarize recent advances in the etiology, diagnosis, and treatment of central hypothyroidism, with an emphasis on diagnostic and therapeutic challenges.</p><p><strong>Methods: </strong>A comprehensive review of the literature was conducted, focusing on genetic and acquired causes, particularly those related to hypothalamic-pituitary tumors and the effects of surgical and radiotherapeutic interventions. Diagnostic approaches and treatment strategies, including levothyroxine therapy and monitoring, are analyzed.</p><p><strong>Results: </strong>Early diagnosis requires simultaneous measurement of free T4 and TSH to prevent neurological sequelae, especially in congenital cases. Central hypothyroidism is associated with risks such as growth and developmental impairment, as well as metabolic and cardiovascular disturbances. Levothyroxine therapy is crucial for correcting hormonal deficits and improving patient outcomes; however, careful dosing is necessary to avoid potential complications, particularly in vulnerable populations.</p><p><strong>Conclusions: </strong>Personalized treatment and continuous monitoring are essential to optimize clinical outcomes and enhance the quality of life in affected individuals. A thorough understanding of central hypothyroidism's etiology and management is necessary to improve early detection and therapeutic strategies.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Polycystic Ovary Syndrome in East Asia: A Review and Meta-Analysis.
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-11 DOI: 10.1016/j.eprac.2025.01.011
Zhao Wu, Guining Liang, Ying Zhang, Renyuan Li

Objectives: The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in women with polycystic ovary syndrome (PCOS). Epidemiologic literature regarding the risk factors for MASLD in PCOS women in East Asia is inconsistent. Studies of PCOS and MASLD in East Asia are restricted by limited data and various biases. Therefore, this meta-analysis was conducted.

Methods: This meta-analysis followed the MOOSE statement. Relevant studies published before July 13, 2023 were retrieved from the PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, Wan Fang, KISS, and Japan medical online databases. The related data were extracted, and the weighted mean difference, odds ratios and 95% confidence intervals were calculated.

Results: Twenty-four studies were included. Through univariate analysis, age, body mass index, waist-to-hip ratio (WHR), blood pressure, alanine transaminase, aspartate transaminase, fasting blood glucose, fasting insulin, homeostatic model assessment for insulin resistance (HOMA-IR), 2-hour postprandial blood glucose, 2 hour insulin, HBA1C, low-density lipoprotein cholesterol, triglyceride, total cholesterol, and testosterone were notably higher in PCOS women with MASLD, with high-density lipoprotein cholesterol markedly lower in PCOS women with MASLD. According to the pooled multivariate analysis, the WHR (P < .001), testosterone (P = .034), and HOMA-IR (P = .02) were substantially greater in PCOS women with MASLD.

Conclusion: MASLD is associated with obesity, IR, and hyperandrogenemia among PCOS women in East Asia. The abnormality of WHR, HOMA-IR, and testosterone suggested early screening of MASLD in this population.

{"title":"Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Polycystic Ovary Syndrome in East Asia: A Review and Meta-Analysis.","authors":"Zhao Wu, Guining Liang, Ying Zhang, Renyuan Li","doi":"10.1016/j.eprac.2025.01.011","DOIUrl":"10.1016/j.eprac.2025.01.011","url":null,"abstract":"<p><strong>Objectives: </strong>The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in women with polycystic ovary syndrome (PCOS). Epidemiologic literature regarding the risk factors for MASLD in PCOS women in East Asia is inconsistent. Studies of PCOS and MASLD in East Asia are restricted by limited data and various biases. Therefore, this meta-analysis was conducted.</p><p><strong>Methods: </strong>This meta-analysis followed the MOOSE statement. Relevant studies published before July 13, 2023 were retrieved from the PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, Wan Fang, KISS, and Japan medical online databases. The related data were extracted, and the weighted mean difference, odds ratios and 95% confidence intervals were calculated.</p><p><strong>Results: </strong>Twenty-four studies were included. Through univariate analysis, age, body mass index, waist-to-hip ratio (WHR), blood pressure, alanine transaminase, aspartate transaminase, fasting blood glucose, fasting insulin, homeostatic model assessment for insulin resistance (HOMA-IR), 2-hour postprandial blood glucose, 2 hour insulin, HBA1C, low-density lipoprotein cholesterol, triglyceride, total cholesterol, and testosterone were notably higher in PCOS women with MASLD, with high-density lipoprotein cholesterol markedly lower in PCOS women with MASLD. According to the pooled multivariate analysis, the WHR (P < .001), testosterone (P = .034), and HOMA-IR (P = .02) were substantially greater in PCOS women with MASLD.</p><p><strong>Conclusion: </strong>MASLD is associated with obesity, IR, and hyperandrogenemia among PCOS women in East Asia. The abnormality of WHR, HOMA-IR, and testosterone suggested early screening of MASLD in this population.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke in the Patient With Type 2 Diabetes.
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-04 DOI: 10.1016/j.eprac.2025.01.010
Terri W Jerkins, David S H Bell

Objective: Persons living with type 2 diabetes mellitus (T2DM) have a significantly greater risk of stroke (1.5 to 3 times higher than normoglycemic individuals). The traditional approach to primary and secondary stroke prevention has been control of risk factors. While this has resulted in prolongation of life in patients with diabetes, the risk for recurrent stroke in these patients still remains higher than in the normoglycemic population, and patients with T2DM post stroke have a poorer quality of life (increases in handicap and death).

Methods: Multiple publications on the pathophysiology which increases stroke in T2DM were reviewed as well as new publications looking at the effect of traditional and new risk factor modification on stroke are summarized.

Results: Traditional risk factor modification is refined with recommended levels of lipids and blood pressure and methods of anticoagulation. More recently, studies with antidiabetic drugs (glucagon-like peptide 1 RA and pioglitazone) have been shown to prevent both primary and secondary stroke in patients with diabetes.

Conclusions: Worldwide, stroke is the second leading cause of death and the third leading cause of disability. Both risk and the outcomes are greatly worsened by the presence of T2DM. Newer recommendations can improve these outcomes.

{"title":"Stroke in the Patient With Type 2 Diabetes.","authors":"Terri W Jerkins, David S H Bell","doi":"10.1016/j.eprac.2025.01.010","DOIUrl":"10.1016/j.eprac.2025.01.010","url":null,"abstract":"<p><strong>Objective: </strong>Persons living with type 2 diabetes mellitus (T2DM) have a significantly greater risk of stroke (1.5 to 3 times higher than normoglycemic individuals). The traditional approach to primary and secondary stroke prevention has been control of risk factors. While this has resulted in prolongation of life in patients with diabetes, the risk for recurrent stroke in these patients still remains higher than in the normoglycemic population, and patients with T2DM post stroke have a poorer quality of life (increases in handicap and death).</p><p><strong>Methods: </strong>Multiple publications on the pathophysiology which increases stroke in T2DM were reviewed as well as new publications looking at the effect of traditional and new risk factor modification on stroke are summarized.</p><p><strong>Results: </strong>Traditional risk factor modification is refined with recommended levels of lipids and blood pressure and methods of anticoagulation. More recently, studies with antidiabetic drugs (glucagon-like peptide 1 RA and pioglitazone) have been shown to prevent both primary and secondary stroke in patients with diabetes.</p><p><strong>Conclusions: </strong>Worldwide, stroke is the second leading cause of death and the third leading cause of disability. Both risk and the outcomes are greatly worsened by the presence of T2DM. Newer recommendations can improve these outcomes.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights of the 2025 American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-01 DOI: 10.1016/j.eprac.2024.11.006
Ricardo Correa MD, EdD
{"title":"Highlights of the 2025 American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia","authors":"Ricardo Correa MD, EdD","doi":"10.1016/j.eprac.2024.11.006","DOIUrl":"10.1016/j.eprac.2024.11.006","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 2","pages":"Pages 263-265"},"PeriodicalIF":3.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methimazole for Prevention of Iodinated Contrast Media–Induced Exacerbation of Thyrotoxicosis in Susceptible Patients 甲巯咪唑用于预防碘化造影剂诱发的易感患者甲亢加重。
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-01 DOI: 10.1016/j.eprac.2024.11.008
Irit Ayalon-Dangur MD, BSc , Einat Magid-Ohayon , Ilan Shimon MD , Eyal Robenshtok MD

Objective

Iodinated contrast media (ICMs) are widely used in a variety of examinations and procedures. The aim of the current study was to investigate the efficacy of methimazole (MMI) in prevention of thyrotoxicosis after ICM exposure.

Methods

A retrospective cohort study included patients aged ≥18 years admitted to a tertiary medical center who underwent ICM examination or procedure and received MMI prior to iodine exposure.

Results

A total of 179 patients with 202 hospitalizations were included. The mean age was 72.3 ± 13.5 years (female, 64%). Nearly all patients (99%) had a history of thyroid disease, and 91% were treated with MMI prior to admission. Seventy-five patients had low thyroid-stimulating hormone (TSH) levels prior to ICM exposure. In this high-risk group, MMI led to normalization of TSH after discharge in 19%, and 64% remained with low TSH levels after discharge but with a small median difference in free thyroxine levels of −0.5 (interquartile range [IQR], −5.9 to 5.2) pmol/L. In the 8 patients with dose increase during hospitalization, treatment with MMI was beneficial with a median free thyroxine decrease of −6.2 (IQR, −9.2 to −1) pmol/L and TSH increase of 0.2 (IQR, 0.02-0.7) mIU/L. In 110 patients with normal TSH levels before admission, with MMI treatment, most (71%) remained euthyroid after discharge, 13% had low TSH levels, and 9% had high TSH levels. In the 15 patients with high TSH levels prior to admission, the TSH levels of only 2 patients normalized, 47% remained with high TSH levels, and 27% had low TSH levels after discharge.

Conclusion

In patients with pre-existing thyrotoxicosis treated with antithyroid drugs, MMI therapy before ICM exposure prevented exacerbations. In patients with low TSH levels before admission, increasing the dose of MMI before exposure led to improvement in thyroid functions after discharge.
目的:碘化造影剂(ICM)广泛用于各种检查和手术。本研究旨在探讨甲巯咪唑对预防 ICM 暴露后甲状腺中毒的疗效:方法:回顾性队列研究,纳入在一家三级医疗中心住院、接受 ICM 检查或手术并在碘暴露前接受甲巯咪唑治疗的 18 岁以上患者:共纳入 179 名患者,202 次住院。平均年龄为 72.3±13.5 岁,64% 为女性。几乎所有患者(99%)都有甲状腺疾病史,91%的患者在入院前接受了甲巯咪唑治疗。75 名患者在接触 ICM 之前 TSH 水平较低。在这一高风险群体中,甲巯咪唑使 19% 的患者出院后 TSH 水平恢复正常,64% 的患者出院后 TSH 水平仍然较低,但 FT4 水平的中位数差异很小,为-0.5,IQR (-5.9)-(5.2) pmol/L。在住院期间剂量增加的 8 名患者中,使用甲巯咪唑治疗是有益的,FT4 下降的中位数为-6.2,IQR 为(-9.2)-(-1)pmol/L,TSH 上升的中位数为 0.2,IQR 为(0.02)-(0.7)mIU/L。在入院前 TSH 水平正常的 110 名患者中,经过甲巯咪唑治疗后,大多数(71%)患者在出院后仍保持甲状腺功能正常,13% 的患者 TSH 水平较低,9% 的患者 TSH 水平较高。入院前促甲状腺激素水平偏高的15名患者中,只有2人的促甲状腺激素水平恢复正常,47%的患者出院后促甲状激素水平仍然偏高,27%的患者促甲状激素水平偏低:结论:对于使用抗甲状腺药物(ATD)治疗的原有甲亢患者,在接触 ICM 前使用甲巯咪唑治疗可防止病情恶化。对于入院前促甲状腺激素水平较低的患者,在暴露前增加甲巯咪唑的剂量可改善出院后的甲状腺功能。
{"title":"Methimazole for Prevention of Iodinated Contrast Media–Induced Exacerbation of Thyrotoxicosis in Susceptible Patients","authors":"Irit Ayalon-Dangur MD, BSc ,&nbsp;Einat Magid-Ohayon ,&nbsp;Ilan Shimon MD ,&nbsp;Eyal Robenshtok MD","doi":"10.1016/j.eprac.2024.11.008","DOIUrl":"10.1016/j.eprac.2024.11.008","url":null,"abstract":"<div><h3>Objective</h3><div>Iodinated contrast media (ICMs) are widely used in a variety of examinations and procedures. The aim of the current study was to investigate the efficacy of methimazole (MMI) in prevention of thyrotoxicosis after ICM exposure.</div></div><div><h3>Methods</h3><div>A retrospective cohort study included patients aged ≥18 years admitted to a tertiary medical center who underwent ICM examination or procedure and received MMI prior to iodine exposure.</div></div><div><h3>Results</h3><div>A total of 179 patients with 202 hospitalizations were included. The mean age was 72.3 ± 13.5 years (female, 64%). Nearly all patients (99%) had a history of thyroid disease, and 91% were treated with MMI prior to admission. Seventy-five patients had low thyroid-stimulating hormone (TSH) levels prior to ICM exposure. In this high-risk group, MMI led to normalization of TSH after discharge in 19%, and 64% remained with low TSH levels after discharge but with a small median difference in free thyroxine levels of −0.5 (interquartile range [IQR], −5.9 to 5.2) pmol/L. In the 8 patients with dose increase during hospitalization, treatment with MMI was beneficial with a median free thyroxine decrease of −6.2 (IQR, −9.2 to −1) pmol/L and TSH increase of 0.2 (IQR, 0.02-0.7) mIU/L. In 110 patients with normal TSH levels before admission, with MMI treatment, most (71%) remained euthyroid after discharge, 13% had low TSH levels, and 9% had high TSH levels. In the 15 patients with high TSH levels prior to admission, the TSH levels of only 2 patients normalized, 47% remained with high TSH levels, and 27% had low TSH levels after discharge.</div></div><div><h3>Conclusion</h3><div>In patients with pre-existing thyrotoxicosis treated with antithyroid drugs, MMI therapy before ICM exposure prevented exacerbations. In patients with low TSH levels before admission, increasing the dose of MMI before exposure led to improvement in thyroid functions after discharge.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 2","pages":"Pages 180-187"},"PeriodicalIF":3.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis GLP-1受体激动剂对2型糖尿病患者HbA1c和体重的剂量-反应关系:一项系统综述和网络meta分析
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-01 DOI: 10.1016/j.eprac.2024.11.013
Qian-Qin Chen MD , Yong Yang PhD , Jian-Ya Xu MD , Junyu Wang PhD , Tuan-Yu Fang MD , Yuan Yuan MD , Chengji Wang PhD , Li Zhang PhD

Objective

To explore the dose-response relationship of GLP-1 RAs in reducing glycated hemoglobin (HbA1c), body weight, and incidence of adverse events among type 2 diabetes mellitus (T2DM) patients.

Methods

This systematic review and network meta-analysis followed the PRISMA guidelines. We conducted a systematic search of PubMed, Medline, Embase, Cochrane Central Register of Controlled Trials, and Web of Science for articles published up to October 20, 2024. Selected studies were randomized controlled trials focusing on adult T2DM patients treated with GLP-1 RAs. Primary outcomes included changes in HbA1c, body weight, and incidence of adverse events. Data extraction was performed by 2 independent researchers. Model-Based Network Meta-Analysis employing a random-effects Bayesian approach was used to synthesize the data.

Results

The analysis included 62 trials with 17 140 participants. The study revealed a nonlinear dose-response relationship for various GLP-1 RAs, indicating significant reductions in HbA1c and body weight. Tirzepatide (10 mg/wk) was found to be particularly effective, reducing HbA1c by −1.76% (95% credible intervals: −2.10 to −1.41) and body weight by −8.63 kg (95% credible intervals: −9.84 to −7.39) without a significant increase in adverse events, highlighting its optimal balance between efficacy and safety. Other GLP-1 RAs also showed significant efficacy, underscoring the overall benefits of this class of medications in managing T2DM.

Conclusion

Our findings indicate a nonlinear dose-response relationship for GLP-1 RAs in managing T2DM. Tirzepatide at a dose of 10 mg/wk is identified as an optimal clinical dose offering a balance between efficacy and safety, contributing to refining T2DM management strategies and potentially enhancing patient outcomes.
目的:探讨GLP-1 RAs在降低T2DM患者HbA1c、体重及不良事件发生率中的量效关系。方法:本系统综述和网络荟萃分析遵循PRISMA指南。我们对PubMed、Medline、Embase、Cochrane Central Register of Controlled Trials和Web of Science进行了系统检索,检索截止到2024年10月20日发表的文章。所选研究为随机对照试验(rct),重点关注GLP-1 RAs治疗的成年T2DM患者。主要结局包括HbA1c、体重和不良事件发生率的变化。数据提取由两名独立研究人员完成。采用随机效应贝叶斯方法的基于模型的网络元分析(MBNMA)对数据进行综合。结果:分析包括62项试验,17140名参与者。该研究揭示了各种GLP-1 RAs的非线性剂量-反应关系,表明HbA1c和体重显著降低。替西帕肽(10mg /周)被发现特别有效,使HbA1c降低-1.76% (95% CrI: -2.10至-1.41),体重降低-8.63 kg (95% CrI: -9.84至-7.39),而不良事件没有显著增加,突出了其在疗效和安全性之间的最佳平衡。其他GLP-1 RAs也显示出显著的疗效,强调了这类药物在治疗T2DM方面的总体益处。结论:我们的研究结果表明GLP-1 RAs在治疗T2DM方面存在非线性剂量-反应关系。替西帕肽10mg /周的剂量被认为是最佳的临床剂量,可以在疗效和安全性之间取得平衡,有助于完善T2DM管理策略,并有可能提高患者的预后。
{"title":"Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis","authors":"Qian-Qin Chen MD ,&nbsp;Yong Yang PhD ,&nbsp;Jian-Ya Xu MD ,&nbsp;Junyu Wang PhD ,&nbsp;Tuan-Yu Fang MD ,&nbsp;Yuan Yuan MD ,&nbsp;Chengji Wang PhD ,&nbsp;Li Zhang PhD","doi":"10.1016/j.eprac.2024.11.013","DOIUrl":"10.1016/j.eprac.2024.11.013","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the dose-response relationship of GLP-1 RAs in reducing glycated hemoglobin (HbA1c), body weight, and incidence of adverse events among type 2 diabetes mellitus (T2DM) patients.</div></div><div><h3>Methods</h3><div>This systematic review and network meta-analysis followed the PRISMA guidelines. We conducted a systematic search of PubMed, Medline, Embase, Cochrane Central Register of Controlled Trials, and Web of Science for articles published up to October 20, 2024. Selected studies were randomized controlled trials focusing on adult T2DM patients treated with GLP-1 RAs. Primary outcomes included changes in HbA1c, body weight, and incidence of adverse events. Data extraction was performed by 2 independent researchers. Model-Based Network Meta-Analysis employing a random-effects Bayesian approach was used to synthesize the data.</div></div><div><h3>Results</h3><div>The analysis included 62 trials with 17 140 participants. The study revealed a nonlinear dose-response relationship for various GLP-1 RAs, indicating significant reductions in HbA1c and body weight. Tirzepatide (10 mg/wk) was found to be particularly effective, reducing HbA1c by −1.76% (95% credible intervals: −2.10 to −1.41) and body weight by −8.63 kg (95% credible intervals: −9.84 to −7.39) without a significant increase in adverse events, highlighting its optimal balance between efficacy and safety. Other GLP-1 RAs also showed significant efficacy, underscoring the overall benefits of this class of medications in managing T2DM.</div></div><div><h3>Conclusion</h3><div>Our findings indicate a nonlinear dose-response relationship for GLP-1 RAs in managing T2DM. Tirzepatide at a dose of 10 mg/wk is identified as an optimal clinical dose offering a balance between efficacy and safety, contributing to refining T2DM management strategies and potentially enhancing patient outcomes.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 2","pages":"Pages 188-197"},"PeriodicalIF":3.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Info for Readers/Subscription page
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-01 DOI: 10.1016/S1530-891X(25)00004-7
{"title":"Info for Readers/Subscription page","authors":"","doi":"10.1016/S1530-891X(25)00004-7","DOIUrl":"10.1016/S1530-891X(25)00004-7","url":null,"abstract":"","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 2","pages":"Pages A1-A2"},"PeriodicalIF":3.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis 阿巴帕肽和特立帕肽对 50 岁及以上女性的疗效比较:真实世界回顾性分析的更新。
IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-02-01 DOI: 10.1016/j.eprac.2024.10.017
Laila Tabatabai MD , Felicia Cosman MD , Jeffrey R. Curtis MD, MS, MPH , Kristi T. DeSapri MD , Clayton T. LaBaume PA-C, MPAS , Jean-Yves Reginster MD, PhD , René Rizzoli MD , Bernard Cortet MD, PhD , Yamei Wang PhD , Joseph Chiodo III PharmD , Bruce H. Mitlak MD

Background

Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture. In the Abaloparatide Comparator Trial In Vertebral Endpoints study, bone mineral density improvements were significantly greater with abaloparatide compared to teriparatide at the total hip and femoral neck. We conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.

Methods

This retrospective observational study used anonymized claims data from ICON’s Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide. The index date was the date of the initial prescription dispensed. Times to first hip fracture, nonvertebral fracture, and serious cardiovascular event were compared between logistic regression-based propensity score–matched cohorts and in predefined subgroups by age, prior antiresorptive use, and prior fracture using Cox proportional hazards models.

Results

Patients (21 676 per cohort) were well matched on 73 baseline parameters. Forty-five percent of patients in the abaloparatide arm and 47% in the teriparatide arm were exposed to treatment for longer than 12 months. Over 18 months (+ 30 days follow-up), 245 (1.1%) and 296 (1.4%) women in the abaloparatide and teriparatide cohorts, respectively, had a hip fracture (HR [95% CI] 0.83 [0.70, 0.98]; P = .027); 947 (4.4%) and 1078 (5.0%) had a nonvertebral fracture (0.88 [0.80, 0.96]; P = .003). There were no significant treatment-subgroup interactions (P ≥ .2). Cardiovascular events were similar between groups.

Conclusions

There were significantly lower rates of hip and nonvertebral fractures with abaloparatide compared to teriparatide, which were consistent across subgroups. No differences in cardiovascular safety were noted between cohorts.
背景:阿巴帕肽和特立帕肽是骨合成代谢治疗药物,适用于绝经后女性和骨折风险较高的男性骨质疏松症患者。在 ACTIVE 研究中,与特立帕肽相比,阿巴帕肽对全髋关节和股骨颈的 BMD 改善明显更大。我们进行了一项回顾性索赔研究,以检查开始接受阿巴帕肽或特立帕肽治疗的 50 岁以上女性的髋部和非椎体骨折以及心血管事件的发生率,这是对之前一项回顾性索赔研究的扩展:这项回顾性观察研究使用了来自 ICON 的 Symphony Health, PatientSource® 的匿名理赔数据,研究对象为年龄≥50 岁、开具过≥1 次阿巴帕肽或特立帕肽处方的女性。索引日期为首次开具处方的日期。使用 Cox 比例危险度模型比较了基于逻辑回归的倾向得分匹配队列和按年龄、既往抗骨吸收剂使用情况和既往骨折情况预定义的亚组中发生首次髋部骨折、非椎体骨折和严重心血管事件的时间:患者(每组 21,676 人)的 73 项基线参数完全匹配。在18个月(+30天随访)内,阿巴帕肽队列和特立帕肽队列中分别有245名(1.1%)和296名(1.4%)女性发生髋部骨折(HR [95% CI] 0.83 [0.70, 0.98];P=0.027);947名(4.4%)和1078名(5.0%)女性发生非椎体骨折(0.88 [0.80, 0.96];P=0.003)。治疗与亚组之间没有明显的交互作用(P≥0.2)。各组的心血管事件发生率相似:结论:与特立帕肽相比,阿巴拉帕肽治疗组的髋部骨折和非椎体骨折发生率明显较低,这在各亚组间是一致的。各组间的心血管安全性无差异。
{"title":"Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis","authors":"Laila Tabatabai MD ,&nbsp;Felicia Cosman MD ,&nbsp;Jeffrey R. Curtis MD, MS, MPH ,&nbsp;Kristi T. DeSapri MD ,&nbsp;Clayton T. LaBaume PA-C, MPAS ,&nbsp;Jean-Yves Reginster MD, PhD ,&nbsp;René Rizzoli MD ,&nbsp;Bernard Cortet MD, PhD ,&nbsp;Yamei Wang PhD ,&nbsp;Joseph Chiodo III PharmD ,&nbsp;Bruce H. Mitlak MD","doi":"10.1016/j.eprac.2024.10.017","DOIUrl":"10.1016/j.eprac.2024.10.017","url":null,"abstract":"<div><h3>Background</h3><div>Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture. In the Abaloparatide Comparator Trial In Vertebral Endpoints study, bone mineral density improvements were significantly greater with abaloparatide compared to teriparatide at the total hip and femoral neck. We conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.</div></div><div><h3>Methods</h3><div>This retrospective observational study used anonymized claims data from ICON’s Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide. The index date was the date of the initial prescription dispensed. Times to first hip fracture, nonvertebral fracture, and serious cardiovascular event were compared between logistic regression-based propensity score–matched cohorts and in predefined subgroups by age, prior antiresorptive use, and prior fracture using Cox proportional hazards models.</div></div><div><h3>Results</h3><div>Patients (21 676 per cohort) were well matched on 73 baseline parameters. Forty-five percent of patients in the abaloparatide arm and 47% in the teriparatide arm were exposed to treatment for longer than 12 months. Over 18 months (+ 30 days follow-up), 245 (1.1%) and 296 (1.4%) women in the abaloparatide and teriparatide cohorts, respectively, had a hip fracture (HR [95% CI] 0.83 [0.70, 0.98]; <em>P</em> = .027); 947 (4.4%) and 1078 (5.0%) had a nonvertebral fracture (0.88 [0.80, 0.96]; <em>P</em> = .003). There were no significant treatment-subgroup interactions (<em>P</em> ≥ .2). Cardiovascular events were similar between groups.</div></div><div><h3>Conclusions</h3><div>There were significantly lower rates of hip and nonvertebral fractures with abaloparatide compared to teriparatide, which were consistent across subgroups. No differences in cardiovascular safety were noted between cohorts.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 2","pages":"Pages 159-168"},"PeriodicalIF":3.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Endocrine Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1